Related references
Note: Only part of the references are listed.Testing for heterogeneity in the utility of a surrogate marker
Layla Parast et al.
BIOMETRICS (2023)
Up Is Down - Pharmaceutical Industry Caution vs. Federal Acceleration of Covid-19 Vaccine Approval
Jerry Avorn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
A model-based approach for simulating adaptive clinical studies with surrogate endpoints used for interim decision-making
Xiaotian Chen et al.
CONTEMPORARY CLINICAL TRIALS COMMUNICATIONS (2020)
Using a surrogate marker for early testing of a treatment effect
Layla Parast et al.
BIOMETRICS (2019)
Estimation of the optimal surrogate based on a randomized trial
Brenda L. Price et al.
BIOMETRICS (2018)
Evaluating surrogate marker information using censored data
Layla Parast et al.
STATISTICS IN MEDICINE (2017)
Robust estimation of the proportion of treatment effect explained by surrogate marker information
Layla Parast et al.
STATISTICS IN MEDICINE (2016)
Surrogacy marker paradox measures in meta-analytic settings
Michael R. Elliott et al.
BIOSTATISTICS (2015)
Effectively Selecting a Target Population for a Future Comparative Study
Lihui Zhao et al.
JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION (2013)
Analysis of randomized comparative clinical trial data for personalized treatment selections
Tianxi Cai et al.
BIOSTATISTICS (2011)
Evaluating Candidate Principal Surrogate Endpoints
Peter B. Gilbert et al.
BIOMETRICS (2008)
Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate
R Eastell et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2003)
A measure of the proportion of treatment effect explained by a surrogate marker
Y Wang et al.
BIOMETRICS (2002)
Share Paper
